Although several anti-fibrotic compounds targeting TGF-β are now on the market and were verified to treat idiopathic pulmonary fibrosis and myelofibrosis [4], no effective treatment has yet been approved to treat liver fibrosis due to its complex pathology and diverse etiology [5,6]. The gene discussed is TGFB1; the disease is Hepatic fibrosis.